Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 4:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 52 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Florbetapir F18 Clear all
Completed Phase 3 Interventional Results available

Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07

NCT01447719
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
22
States / cities
Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects

NCT02103894
View directory record Official record
Conditions
Alzheimer's Disease (AD), Parkinson's Disease (PD), Chronic Traumatic Encephalopathy (CTE), Progressive Supranuclear Palsy (PSP), Frontal Temporal Dementia (FTD), Pick's Disease, Tauopathies
Interventions
[18F]T807 ([18F]MNI-777)
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 2, 2026, 4:08 AM EDT
Recruiting Not applicable Interventional

Molecular Imaging of Primary Amyloid Cardiomyopathy

NCT02641145
View directory record Official record
Conditions
Amyloidosis, Primary, Cardiomyopathy
Interventions
F-18 florbetapir/C-11 acetate PET, MRI, N-13 ammonia PET
Radiation · Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 99 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 1Phase 2 Interventional

Diagnostic Utility of F-18 Florbetapir PET/MR in Peripheral Nerve Amyloidosis

NCT03019029
View directory record Official record
Conditions
Amyloidosis
Interventions
18-F Florbetapir PET/MR scan
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 2, 2026, 4:08 AM EDT
Active, not recruiting Phase 4 Interventional

Effects of Brain Beta-Amyloid on Postoperative Cognition

NCT01606488
View directory record Official record
Conditions
Postoperative Cognitive Dysfunction
Interventions
Florbetapir F 18 (18F-AV-45), no intervention
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
65 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 1 Interventional Results available

A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease

NCT03019536
View directory record Official record
Conditions
Alzheimer Disease
Interventions
LY3303560 - IV, Placebo - IV, Florbetapir F 18, Flortaucipir F18
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
Melbourne, Florida • Orlando, Florida • Port Orange, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy Volunteers

NCT01565330
View directory record Official record
Conditions
Alzheimer Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
35 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
3
States / cities
West Palm Beach, Florida • North East, Maryland • Clementon, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 18, 2012 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Not applicable Interventional Results available

Non-invasive Blood-brain Barrier Opening in Alzheimer's Disease Patients Using Focused Ultrasound

NCT04118764
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Neuronavigation-guided single-element focused ultrasound transducer, Definity, Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents, Positron Emission Tomography (PET), Amyvid
Device · Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
50 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)

NCT01503944
View directory record Official record
Conditions
Dementia With Lewy Bodies, Alzheimer's Disease, Parkinson's Disease
Interventions
18F-AV-133, 18F-AV-45
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Sun City, Arizona • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 14, 2012 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

A Preliminary Study of 18F-AV-45 in Alzheimer's Disease and Healthy Elderly Volunteers

NCT01565291
View directory record Official record
Conditions
Alzheimer Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
3
States / cities
Baltimore, Maryland • North East, Maryland • Long Branch, New Jersey
Source: ClinicalTrials.gov public record
Updated May 18, 2012 · Synced Oct 2, 2026, 4:08 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease

NCT07787169
View directory record Official record
Conditions
Alzheimer Disease, Amyloid, Plaque, Amyloid, Healthy Volunteers
Interventions
LY4405094, Placebo, Florbetapir F18, Florbetaben F 18
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
13
States / cities
Anaheim, California • Irvine, California • Los Alamitos, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 2, 2026, 4:08 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Aftobetin-HCl and Fluorescence Detection Measured by Sapphire II to Determine the Number and Timing of Administrations

NCT02928211
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Sapphire II, Aftobetin-HCl, Positron Emission Tomography
Device · Drug · Radiation
Lead sponsor
Cognoptix, Inc.
Industry
Eligibility
25 Years to 90 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Oct 2, 2026, 4:08 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)

NCT07843459
View directory record Official record
Conditions
Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid, Plasma
Interventions
LY4560736, Placebo, Florbetapir F18, Florbetaben F 18
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
13
States / cities
Anaheim, California • Irvine, California • Los Alamitos, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Evaluation of Florbetapir F 18 (18F-AV-45)

NCT01518374
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Neurodegenerative Diseases
Interventions
Florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,768 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2017
U.S. locations
26
States / cities
Phoenix, Arizona • Sun City, Arizona • Davis, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 2, 2026, 4:08 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Alzheimer's Disease Neuroimaging Initiative 2

NCT01231971
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD), Significant Memory Concern (SMC), Early Mild Cognitive Impairment (EMCI), Late Mild Cognitive Impairment (LMCI)
Interventions
Florbetapir, Flortaucipir
Drug
Lead sponsor
University of Southern California
Other
Eligibility
55 Years to 90 Years
Enrollment
1,182 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
53
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 2, 2026, 4:08 AM EDT
Completed No phase listed Observational

Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials

NCT02918539
View directory record Official record
Conditions
Alzheimer Disease, Cognition Disorders
Interventions
florbetapir F 18 PET scan
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
75
States / cities
Glendale, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Plasma P-tau2017 and Quantitative Amyloid PET Imaging

NCT05164536
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Amyvid
Drug
Lead sponsor
Invicro
Other
Eligibility
70 Years and older
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 2, 2026, 4:08 AM EDT
Withdrawn Phase 2 Interventional

Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease

NCT02667496
View directory record Official record
Conditions
Dementia Alzheimer's Type
Interventions
Sargramostim GZ402664, Placebo, Florbetapir F18
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 7, 2017 · Synced Oct 2, 2026, 4:08 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Imaging Characteristics of a Follow-up 18F-AV-1451 Scan

NCT02051764
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Flortaucipir F18, Florbetapir F 18, Brain PET Scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
4
States / cities
Newport Beach, California • Orange, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2020 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects

NCT02016560
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
florbetapir F 18, Flortaucipir F18, Brain PET Scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
20 Years and older
Enrollment
383 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
27
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Oct 2, 2026, 4:08 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease

NCT07787182
View directory record Official record
Conditions
Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid
Interventions
LY4405094, Placebo, Florbetapir F18, Florbetaben F 18
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
13
States / cities
Anaheim, California • Irvine, California • Los Alamitos, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45)

NCT00857506
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
8
States / cities
Scottsdale, Arizona • Tucson, Arizona • Costa Mesa, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2013 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients

NCT00857532
View directory record Official record
Conditions
Parkinson's Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
60 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 11, 2013 · Synced Oct 2, 2026, 4:08 AM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

NCT01703702
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
florbetapir (18F)
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years to 90 Years
Enrollment
641 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
21
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2016 · Synced Oct 2, 2026, 4:08 AM EDT